AFRICA 341 benefits, are we doing more harm than good in the long run? Having said that, the inferences made from the Sipahi et al. 1 study that the risk of cancer is increased in patients taking ARBs is concerning to say the least.
1 study that the risk of cancer is increased in patients taking ARBs is concerning to say the least.
The most important tenant of clinical trials is to determine which statistical endpoints need to be defined prior to commencing any study, and any posthoc analysis needs to be treated with the contempt that it deserves. To group a number of studies involving the ARBs (meta-analysis) and to extrapolate that there is an increased incidence of cancer in certain groups of patients is bad medicine and the outcomes of this report should not influence the use of these agents in patients.
The analysis is contradictory -there is an increase in lung cancer, which is claimed to be statistically significant in the group of patients receiving ARBs, yet the incidence of other cancers is decreased or the same. The group of patients that would typically be enrolled in these studies is firstly, a group of patients that are high risk for lung cancer, as they no doubt include a skewed bias in favour of smokers. All these factors would need to be included in the statistical design of the study prior to drawing these conclusions.
At this stage, I can find no reason to be concerned about the use of ARBs in patients. Far more reliable prospective, randomised data need to be presented prior to considering withdrawing this class of drug from the market.
It is rather ironic that there is a concern regarding a slight increase in cancer incidence in patients using ARBs in a retrospective analysis of numerous studies, yet a medication that is used widely and is known to have far greater impact on the development of breast cancer in women is prescribed in far greater numbers on a daily basis by doctors around the worldoestrogen replacement therapy -without as much as a mention in widely read medical journals! 
Fda committee unanimously recommends approval of dabigatran etexilate for stroke prevention in atrial fibrillation
The US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee recently voted 9 to 0 in favour of recommending dabigatran etexilate for stroke prevention in patients with atrial fibrillation (AF). For decades, vitamin K antagonists such as warfarin have been the most efficacious therapeutic option for stroke prevention in AF. Current recommendations for patients with non-valvular atrial fibrillation treated with warfarin recommend maintaining an international normalised ratio (INR) in the range of 2.0-3.0 through frequent blood monitoring and dose adjustments, which can be challenging for physicians and patients.
In RE-LY ® , dabigatran etexilate demonstrated efficacy without the need for ongoing INR monitoring or dose adjustments. Furthermore, there were no food restrictions on those taking dabigatran in RE-LY ® . A total of 6.3 million people in the USA, Japan, Germany, Italy, France, UK and Spain were living with AF in 2007 and this is expected to increase to 7.5 million by 2017, primarily due to the ageing population. 1 'We are pleased with the committee's recommendation, which marks an important step in advancing care for patients with atrial fibrillation', said Prof Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim. 'We believe dabigatran etexilate will offer patients and doctors the first new treatment option for stroke prevention in atrial fibrillation in more than 50 years. We look forward to working with the FDA as it finalises its review of dabigatran.' Pradaxa (75 and 110 mg) is currently only registered in South Africa for the prevention of venous thromboembolic events in patients who have undergone hip-and knee-replacement surgery. For full prescribing information refer to the package insert approved by the Medicines Regulatory Authority.
